Journal
SCIENCE
Volume 338, Issue 6106, Pages 491-495Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1218071
Keywords
-
Categories
Funding
- National Institute of Neurological Disorders and Stroke [R01NS75345, R01NS39559]
- National Multiple Sclerosis Society
- Adelson Medical Research Foundation
- Mathers Charitable Foundation
- New York State Stem Cell Research Program (NYSTEM)
Ask authors/readers for more resources
The diseases of myelin are among the most prevalent and disabling conditions in neurology. These diseases include both the vascular and inflammatory demyelinating disorders of adulthood, as well as the childhood leukodystrophies and cerebral palsy. These fundamentally glial disorders may be amenable to treatment by glial progenitor cells (GPCs), which give rise to astroglia and myelin-producing oligodendrocytes. Given the development of new methods for generating and isolating human GPCs, the myelin disorders may now be compelling targets for cell-based therapy. In addition, the efficient engraftment and expansion of human GPCs in murine hosts has led to the development of human glial chimeric mouse brains, which provides new opportunities for studying the species-specific roles of human glia in cognition, as well as in disease pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available